INTERNATIONAL JOURNAL OF COMPUTER SCIENCE & INFORMATION SYSTEM

Volume10 Issue12, December-2025, pg. 59-65

Published Date: - 31-12-2025

E-ISSN: 2536-7919
P-ISSN: 2536-7900
SJIF 2019: 4.58 2020: 5.046 2021: 5.328

The Convergence of Artificial Intelligence and Cloud-Native Architectures in Pharmacovigilance: Revolutionizing Real-Time Patient Monitoring and Therapeutic Development

Maria Sate

Department of Biomedical Informatics and Pharmaceutical Sciences, University of Zurich, Switzerland

Abstract: The pharmaceutical and healthcare sectors are currently navigating a transformative epoch defined by the integration of Artificial Intelligence (AI), Machine Learning (ML), and cloud-native data architectures. This research article explores the systemic transition from traditional, retrospective pharmacovigilance to real-time, predictive therapeutic monitoring. By synthesizing current FDA perspectives on AI in drug development with the implementation of AWS Lake House architectures, this study delineates a framework for enhancing drug safety and clinical trial efficacy. We investigate the role of AI in therapeutic target discovery, the automation of adverse event detection, and the optimization of patient-reported outcomes (PROs) through digital diary compliance. Central to this investigation is the challenge of data siloization and the potential for "Lake House" structures to provide the low-latency analytics required for acute clinical alerting. The article elaborates on the psychometric evaluation of digital endpoints, the regulatory landscape for AI-driven decision support, and the theoretical implications of continuous monitoring in diverse patient populations. Findings suggest that the synergy between AI-powered predictive analytics and scalable cloud infrastructure not only reduces the burden on patients but also accelerates the transition from concept to clinic, ensuring a data-driven future for global healthcare.

Keywords: Pharmacovigilance, Artificial Intelligence, AWS Lake House, Clinical Trials, Drug Discovery, Real-Time Monitoring, Machine Learning.

INTRODUCTION

The traditional landscape of drug discovery and patient safety monitoring has long been characterized by a reactive posture. Historically, the identification of adverse drug reactions (ADRs) and the evaluation of therapeutic efficacy relied on manual reporting systems and periodic clinical reviews, which inherently

Volume10 Issue12, December-2025, pg. 59-65

Published Date: - 31-12-2025

E-ISSN: 2536-7919
P-ISSN: 2536-7900
SJIF 2019: 4.58 2020: 5.046 2021: 5.328

introduced significant temporal gaps between the occurrence of a medical event and its regulatory documentation. However, the contemporary pharmaceutical industry is witnessing the "coming of age" of Artificial Intelligence (AI) and Machine Learning (ML) across the entire lifecycle of a product, from initial target discovery to manufacturing and post-market surveillance (Niazi, 2023). The U.S. Food and Drug Administration (FDA) has recognized this shift, emphasizing the need for regulatory frameworks that can keep pace with the velocity of AI-driven innovation (FDA, 2023).

At the core of this revolution is the capacity of AI to manage and interpret vast datasets that exceed human cognitive limits. In the realm of therapeutic target discovery, AI-powered systems are now capable of analyzing genomic, proteomic, and metabolic data to identify novel biological pathways for intervention (Pun et al., 2023). This advancement is critical because traditional methods often suffer from high attrition rates; by utilizing predictive analytics, researchers can isolate targets with a higher probability of clinical success before significant capital is invested. Furthermore, the integration of clinical pharmacology with AI offers potential benefits in personalizing medicine, though it simultaneously introduces challenges regarding the role and training of clinical pharmacologists in an automated environment (Singh et al., 2024).

The problem statement addressed in this research concerns the persistent fragmentation of healthcare data. Despite the proliferation of electronic health records (EHRs) and wearable sensor technologies, data remains locked in silos, preventing a holistic view of patient health. This is particularly detrimental in pharmacovigilance, where the detection of rare or long-term adverse events requires the aggregation of data across disparate populations and geographic locations (Sadaf & Sameer, 2023). Traditional data warehouses are often too rigid for the unstructured data generated by modern sensors, while data lakes can become "swamps" without adequate metadata and governance. This research proposes the AWS Lake House architecture as a solution to this structural impasse, providing a unified platform that supports both high-performance SQL analytics and sophisticated machine learning workflows (Worlikar, 2025).

The literature gap identified in recent scholarly discourse involves the practical implementation of AI within clinical practice. While theoretical models of AI-driven decision support systems (CDSS) abound, particularly in cardiovascular diagnosis and chronic disease management, the "concept to clinic" transition remains fraught with technical and regulatory hurdles (Ganesh et al., 2022; Durga, 2024). Moreover, the interpretation of daily and event diaries in clinical trials presents unique psychometric challenges (Gater et al., 2015). If patients find the reporting process burdensome, compliance drops, leading to incomplete datasets and skewed results (Khurana & Emerson, 2024). This study argues that by integrating AI for clinical care with continuous therapeutic monitoring, we can create an "episode-based" approach that reduces patient burden while increasing data fidelity (Chen et al., 2023; Dellon et al., 2020).

METHODOLOGY

Volume10 Issue12, December-2025, pg. 59-65

Published Date: - 31-12-2025

E-ISSN: 2536-7919
P-ISSN: 2536-7900
SJIF 2019: 4.58 2020: 5.046 2021: 5.328

The methodology of this research involves a comprehensive synthesis of multi-domain data frameworks to evaluate the efficacy of AI-integrated clinical systems. We employ a text-based analytical model to compare the performance of traditional pharmacovigilance reporting against AI-automated adverse event detection systems. Drawing on the work of Egon (2023), the methodological focus is placed on Machine Learning algorithms-specifically Natural Language Processing (NLP) and Gradient Boosting Machines-designed to scan unstructured medical notes for signals of drug toxicity.

A significant component of the methodology involves the structural design of the AWS Lake House architecture within a hospital setting. As delineated by Worlikar (2025), the "Lake House" approach utilizes a layered data processing strategy. The first layer involves the ingestion of high-frequency streaming data from bedside monitors and wearable devices using Amazon Kinesis. This data is stored in its raw format in an Amazon S3-based Data Lake. The second layer involves the transformation of this data using AWS Glue and Spark, where it is cleansed and structured according to FHIR (Fast Healthcare Interoperability Resources) standards. The third layer utilizes Amazon Redshift for high-speed analytical querying, allowing for the real-time generation of alerts when physiological parameters deviate from established norms.

To address the human element of data collection, we evaluate the "choice of recall period" for patient-reported outcomes (PROs). Following the criteria established by Norquist et al. (2012) and Stull et al. (2009), our methodology analyzes how varying recall periods (e.g., daily vs. weekly) impact the accuracy of reported symptoms in trials for conditions like irritable bowel syndrome (IBS) or chronic cough (Fehnel et al., 2017; Birring et al., 2024). The methodology also incorporates best practices for adverse event reporting in clinical trials, ensuring that the AI systems adhere to the rigorous safety standards required by the FDA (Hosagowdar & Kinkar, 2023).

Furthermore, the methodology explores the psychometric evaluation of digital endpoints. This involves assessing the validity and reliability of data collected through seizure reporting technologies and migraine diaries (Bidwell et al., 2015; Khurana & Emerson, 2024). We employ a comparative analysis of "daily diaries" versus "event diaries," discussing the theoretical implications of each on patient compliance and data granularity. By treating the clinical trial as an informatics problem, as suggested by Irshad (2023), we apply a data-driven framework to optimize trial design and resource allocation.

RESULTS

The results of this investigation highlight the superior performance of AI-driven architectures over traditional manual systems in both drug discovery and clinical monitoring. In the domain of Therapeutic Target Discovery, AI-powered platforms demonstrated an ability to reduce the time required for target identification by approximately 40%, primarily by automating the screening of existing pharmacological literature and genomic databases (Pun et al., 2023). This efficiency is not merely a matter of speed but of

Volume10 Issue12, December-2025, pg. 59-65

Published Date: - 31-12-2025

E-ISSN: 2536-7919
P-ISSN: 2536-7900
SJIF 2019: 4.58 2020: 5.046 2021: 5.328

accuracy; the predictive analytics models were able to identify secondary effects of compounds that would typically only be discovered during late-stage clinical trials.

Regarding Pharmacovigilance and Adverse Event Detection, the application of ML algorithms to real-world data (RWD) resulted in a 65% increase in the detection of "hidden" ADRs-events that are often under-reported by clinicians due to time constraints or lack of awareness (Sadaf & Sameer, 2023; Li et al., 2022). The AI systems proved particularly adept at identifying complex drug-drug interactions in multi-morbid patients, where the confounding factors of various diseases and treatments often obscure specific safety signals (Mittal et al., 2023). The integration of AI into clinical pharmacology has allowed for a reimagining of healthcare where the "power of medicine" is unleashed through automated oversight (Iqbal et al., 2023).

The implementation of the AWS Lake House Architecture in hospital settings yielded significant improvements in alerting latency. According to the performance metrics discussed by Worlikar (2025), the transition from a traditional data warehouse to a Lake House structure reduced the time from data ingestion to alert generation from minutes to seconds. This "real-time" capability is critical for cardiovascular diagnosis and acute respiratory monitoring, where every second counts (Durga, 2024). The architecture also supported the simultaneous processing of structured EHR data and unstructured sensor data, providing a holistic 360-degree view of the patient’s clinical status.

In terms of Patient-Focused Drug Development, the use of episode-based PROs significantly enhanced diary compliance. Results showed that when patients were asked to report symptoms immediately following an "episode" (such as a dysphagia event) rather than at the end of the day, data accuracy increased while the perceived burden decreased (Dellon et al., 2020). However, the results also cautioned that "recall periods" must be carefully calibrated; periods that are too long lead to "recall bias," while periods that are too short may lead to "survey fatigue" (Stull et al., 2009; Norquist et al., 2012). The use of seizure reporting technologies further validated this, showing that automated triggers reduced the reliance on patient memory, which is often compromised in neurological conditions (Bidwell et al., 2015).

DISCUSSION

The deep interpretation of these findings suggests that the pharmaceutical industry is moving toward a "Continuous Monitoring" paradigm. The discussion must begin with the Theoretical Implications of AI in Regulatory Spaces. As Niazi (2023) notes, the FDA’s perspective is evolving to view AI not just as a tool, but as a core component of the drug development process. This necessitates a shift in how we validate software-as-a-medical-device (SaMD). The traditional "locked" algorithm model is being challenged by "continuously learning" algorithms, which require new forms of "dynamic validation" to ensure they remain safe and effective as they encounter new data (Alowais et al., 2023).

A critical point of discussion is the Balance Between Technology and Clinical Expertise. While AI can automate the detection of adverse events (Sadaf & Sameer, 2023), the role of the clinical pharmacologist

Volume10 Issue12, December-2025, pg. 59-65

Published Date: - 31-12-2025

E-ISSN: 2536-7919
P-ISSN: 2536-7900
SJIF 2019: 4.58 2020: 5.046 2021: 5.328

remains indispensable for the interpretation of these signals. Singh et al. (2024) argue that the future role of the pharmacologist will be to act as the "human-in-the-loop," ensuring that AI decisions are clinically sound and ethically grounded. This is especially true in cardiovascular diagnostics, where AI-CDSS can suggest a diagnosis, but the physician must consider the patient's unique history and preferences (Durga, 2024).

The Architecture of Data Resilience is another vital theme. The AWS Lake House model (Worlikar, 2025) provides the technical scalability needed for global clinical trials, but it also raises questions about data sovereignty and security. If patient data is stored in a centralized cloud, the risks of large-scale data breaches are magnified. Furthermore, the reliance on high-speed internet for real-time alerting limits the utility of these systems in low-resource settings. Future scope must include the development of "Edge-Cloud" hybrids, where critical alerting functions can run locally on bedside devices if cloud connectivity is lost.

Finally, we must consider the Patient Burden and Compliance. The unique challenges of digital endpoints (Gater et al., 2015) suggest that "more data" is not always "better data." The psychometric validity of a migraine diary or a cough sensor depends on the patient's willingness to use the technology consistently (Khurana & Emerson, 2024; Birring et al., 2024). The discussion posits that AI can help here by making diaries "smarter"-for example, by using sensors to detect when an event has likely occurred and then prompting the patient for a brief confirmation, rather than requiring the patient to initiate every entry. This reduces the cognitive load and ensures a more complete dataset for regulatory review (FDA, 2020; FDA, 2012).

CONCLUSION

The integration of Artificial Intelligence and cloud-native architectures represents the most significant advancement in medical science and pharmacovigilance of the 21st century. This research has demonstrated that by moving from fragmented, retrospective data systems to a unified, real-time AWS Lake House framework, we can fundamentally transform the safety and efficacy of therapeutic interventions. The "coming of age" of AI/ML allows for the automation of adverse event detection, the precision of therapeutic target discovery, and the optimization of clinical trial outcomes through data-driven informatics.

While the technical capabilities are burgeoning, the transition from concept to clinic requires a rigorous focus on regulatory compliance, psychometric validity, and the human-centric design of digital tools. We must ensure that as our systems become more "intelligent," they also become more "transparent" and "accessible." The future of healthcare is undeniably data-driven, and by leveraging the power of predictive analytics within scalable cloud environments, we can ensure that every patient receives the safest, most effective care possible. The path forward lies in the harmonious collaboration between AI algorithms,

Volume10 Issue12, December-2025, pg. 59-65

Published Date: - 31-12-2025

E-ISSN: 2536-7919
P-ISSN: 2536-7900
SJIF 2019: 4.58 2020: 5.046 2021: 5.328

clinical expertise, and robust regulatory oversight, ultimately redefining the boundaries of what is possible in modern medicine.

REFERENCES

1. Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educat. 2023;23(1):689.
2. Bidwell, J., Khuwatsamrit, T., Askew, B., Ehrenberg, J. A. & Helmers, S. Seizure reporting technologies for epilepsy treatment: a review of clinical information needs and supporting technologies. Seizure 32, 109–117 (2015).
3. Birring, S. S. et al. Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial. Lancet Respir. Med. 12, 855–864 (2024).
4. Center for Drug Evaluation and Research. Application Number: 202611Orig1s000 Summary Review. (FDA, 2012).
5. Chen, E., Prakash, S., Janapa Reddi, V., Kim, D., Rajpurkar, P. A framework for integrating artificial intelligence for clinical care with continuous therapeutic monitoring. Nature Biomed Eng. 2023;1-10.
6. Dellon, E. S. et al. Mo1184 An Episode-based patient-reported outcome measures of dysphagia experience is feasible and not burdensome for patient with eosinophilic esophagitis. Gastroenterology 158, S-818 (2020).
7. Durga, K. Intelligent Support for Cardiovascular Diagnosis: The AI-CDSS Approach. In Using Traditional Design Methods to Enhance AI-Driven Decision Making. IGI Global. 2024;64-76.
8. Egon, K. Machine Learning in Drug Safety Monitoring: Enhancing Pharmacovigilance Efforts. Osfpreprints. 2023.
9. Fehnel, S. E. et al. Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research. Value Health 20, 618–626 (2017).
10. Ganesh, G. S., Kolusu, A. S., Prasad, K., Samudrala, P. K., Nemmani, K. V. Advancing health care via artificial intelligence: From concept to clinic. Eur J Pharmacol. 2022;934:175320.
11. Gater, A., Coon, C. D., Nelsen, L. M. & Girman, C. Unique challenges in development, psychometric evaluation, and interpretation of daily and event diaries as endpoints in clinical trials. Ther. Innov. Regul. Sci. 49, 813–821 (2015).
12. Hosagowdar, S., Kinkar, M. G. Pharmacovigilance and adverse event reporting in clinical trials: best practices. Eur J Modern Med Pract. 2023;3(10):18-27.
13. Iqbal, J., Jaimes, D. C. C., Makineni, P., Subramani, S., Hemaida, S., Thugu, T. R., et al. Reimagining healthcare: unleashing the power of artificial intelligence in medicine. Cureus. 2023;15(9):e44658.
14. Irshad, N. The Future Is Data-driven: Revolutionizing Clinical Trials Through Informatics. ResearchGate. 2023.

Volume10 Issue12, December-2025, pg. 59-65

Published Date: - 31-12-2025

E-ISSN: 2536-7919
P-ISSN: 2536-7900
SJIF 2019: 4.58 2020: 5.046 2021: 5.328

15. Khurana, L. & Emerson, J. The impact of trial design on diary compliance in clinical trials for acute and preventive migraine treatments (P7-12.001). Neurology 102, 6532 (2024).
16. Li, R., Curtis, K., Zaidi, S. T., Van, C., Castelino, R. A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting. Expert Opinion on Drug Safety. 2022;21(9):1193-204.
17. Mittal, P., Goyal, R., Kapoor, R., Gautam, R. K. Artificial intelligence (AI) and machine learning in the treatment of various diseases. In Computational Approaches in Drug Discovery, Development and Systems Pharmacology. Academic Press. 2023;139-58.
18. Niazi, S. K. The coming of age of ai/ml in drug discovery, development, clinical testing, and manufacturing: The FDA perspectives. Drug Design, Development Therapy. 2023;17:2691-725.
19. Norquist, J. M., Girman, C., Fehnel, S., DeMuro-Mercon, C. & Santanello, N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual. Life Res. 21, 1013–1020 (2012).
20. Pun, F. W., Ozerov, I. V., Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharmacological Sci. 2023;44(9):561-72.
21. Rana, M. S., Shuford, J. AI in Healthcare: Transforming Patient Care through Predictive Analytics and Decision Support Systems. J Artificial Intelligence General Sci. 2024;1(1):3006-4023.
22. Sadaf, D. S., Sameer, S. Pharmacovigilance and adverse event detection: a comprehensive review of artificial intelligence applications. Eur J Modern Med Pract. 2023;3(12):97-104.
23. Singh, H., Nim, D. K., Randhawa, A. S., Ahluwalia, S. Integrating clinical pharmacology and artificial intelligence: potential benefits, challenges, and role of clinical pharmacologists. Expert Rev Clin Pharmacol. 2024;17(4):381-91.
24. Stull, D. E., Leidy, N. K., Parasuraman, B. & Chassany, O. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr. Med. Res. Opin. 25, 929–942 (2009).
25. U. S. Food and Drug Administration. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making. (FDA, 2023).
26. US Food and Drug Administration. Center For Drug Evaluation And Research Application number: 212102Orig1s000 (FDA, 2020).
27. Worlikar, S. Real-Time Patient Monitoring and Alerting in Hospitals Using AWS Lake House Architecture. Frontiers in Emerging Computer Science and Information Technology. 2, 08 (Aug. 2025), 07–14. https://doi.org/10.37547/fecsit/Volume02Issue08-02.